Centessa Pharmaceuticals PLC (CNTA): Price-to-Revenue Ratio

Brandmark of Centessa Pharmaceuticals plc (CNTA)

The growth of Centessa Pharmaceuticals (CNTA) is based on the success of its selective orexin agonist and FDA approval. The market cap-to-revenue ratio confirms this trend, and the 393.40 value captures this metric. While geopolitical tensions complicate international trials, intensive R&D in neurobiology creates potential for breakthrough discoveries in the treatment of rare disorders.

CNTA Centessa Pharmaceuticals P/S Multiple (03/31/2024 - 05/07/2026)

Analytical breakdowns for centessa.com (CNTA)

- current quotes and average value forecast:
General company analysis:CNTA - Centessa Pharmaceuticals plc
Mass-produced product of Centessa Pharmaceuticals

The P/S ratio determines the market value of a business per unit of revenue generated, allowing for an assessment of the premium paid for an asset in the absence of net profit. By analyzing the ratio of share price to sales volume, an investor can evaluate the capitalization potential of Centessa Pharmaceuticals (CNTA), whose value is currently based on the organic development of its pipeline and the prospects of strategic partnerships with pharma behemoths.